Every year, ASCO arrives with a theme. Most quietly disappear into the background by the end of the opening session, overtaken by survival curves, late-breaking data and the relentless pace of oncology innovation.
This year’s theme was different. Translation.
More than a congress slogan, it felt like a call to action. The opening message was that oncology’s job isn’t just to generate innovation, but to ensure that innovation makes a difference where it matters.
That means translating emerging science into care that works meaningfully in practice. And translating clinical research into real-world impact across different healthcare systems, settings and communities.
For those working in healthcare marketing, there’s another challenge too: translating complex science into communications and experiences that help people understand, trust and act on it.
Because, as ASCO President Eric Small put it: “What matters to patients is what matters most.”
This year, breakthroughs were only part of the story.
What stood out most was how much smarter oncology is becoming in terms of when, why and how to treat. Across tumour types, discussions repeatedly returned to the same themes: intervening earlier, understanding disease more precisely, tailoring treatment more effectively and making better use of the tools available to clinicians.
Ultimately, ASCO 2026 wasn’t just about hazard ratios and first-in-class molecules. It was about exploring a broader question: how do we translate scientific progress into better outcomes for patients? Here are the trends that stood out.
Read the article in full here.